These findings suggested that automatic activation of the STAT3/CCL20/CCR6 cascade was involved in CTCL lymphomagenesis and that disruption of CCL20-CCR6 interaction could be a key therapeutic strategy against advanced CTCL. This evidence concerns the gene CCL20 and primary cutaneous T-cell non-Hodgkin lymphoma.